• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

    14.32 -1.75 (-10.91%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 91,565
    Open 16.28
    Bid (Size) 14.00 (14)
    Ask (Size) 17.00 (2)
    Prev. Close 16.08
    Today's Range 14.03 - 16.28
    52wk Range 5.005 - 18.70
    Shares Outstanding 101,102,152
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
    Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
    Via Benzinga
    Atara Biotherapeutics Announces Changes to Its Board of Directors
    From Atara Biotherapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +1.2%
    +1.2%
    1 Month
    +18.2%
    +18.2%
    3 Month
    +54.0%
    +54.0%
    6 Month
    +144.9%
    +144.9%
    1 Year
    +75.8%
    +75.8%

    More News

    Read More
    Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics Announces Pricing of $16 Million Offering
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
    Via Benzinga
    Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates
    Via Benzinga
    Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip
    Via Stocktwits
    Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
    Via Benzinga
    US Stocks Edge Lower; Retail Sales Increase Less Than Expected
    Via Benzinga
    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire
    Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
    From Atara Biotherapeutics, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?
    Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market
    What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
    The current price of Atara Biotherapeutics, Inc. - Common Stock is 14.32
    When was Atara Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 10/10/25 04:00 PM ET
    What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
    The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 1.45B
    How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
    Atara Biotherapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.